The gloves contain a special formulation to reduce scattered radiation exposure
The new addition provides fresh clinical insight without extra time or radiation
The facility has experienced significant expansion since its establishment in 2006
Conducted at at New Jersey facility
Four of nine evaluable patients responded to TILT-123 combined with pembrolizumab and pegylated liposomal doxorubicin, including two complete responses
Sign in to your account